[Mark11]

ACSO Study - KRd plus Auto SCT

by Mark11 on Thu May 21, 2015 7:28 pm

I noticed this study from ASCO 2015. KRD (Kyprolis - Revlimid - DEX) plus auto sct shows an 86% stringent CR rate. Nice table at the bottom showing the stringent CR rate rising as each part of therapy is completed. Hopefully these remissions will prove to be durable!

"Background: In a phase I/II study of combination treatment with CFZ, LEN, and DEX (KRd) without ASCT, KRd provided a high rate of sCR (55%) in NDMM patients (pts) and 3-year progression-free survival and OS rates of 79% and 96% (Jakubowiak et al. Blood 2012;120:1801-9; Jasielec et al. Blood 2013;122:3220). To further improve response and outcomes, we designed a phase II study to assess activity of extended treatment with KRd and ASCT. Methods: Pts received 28-day (d) cycles of CFZ 20/36 mg/m2IV (d1, 2, 8, 9, 15, 16), LEN 25mg PO (d1–21), and DEX 40/20 mg PO wkly (cycles1–4 induction/5–8 consolidation) with ASCT after cycle 4. For cycles 8–18, KRd was given with a modified CFZ schedule (d1, 2, 15, 16) and then LEN alone after cycle 18. Response was assessed by IMWG plus nCR. The primary endpoint is the rate of stringent complete response (sCR) at the end of cycle 8, with statistical hypothesis that the improvement of sCR from 30% (KRd without ASCT) to >50% will represent added benefit of ASCT."


"Conclusions: KRd with ASCT for NDMM resulted in higher sCR rates than KRd without ASCT and high rate of MRD-negative disease, suggestive of benefit of adding ASCT to KRd treatment. The results to date compare favorably to any prior treatment of NDMM."

http://abstracts.asco.org/156/AbstView_156_150628.html

[JPC]

Re: ACSO Study - KRd plus Auto SCT

by JPC on Fri May 22, 2015 8:55 am

Mark:

Really great job at squirreling out the latest, most relevant research. Copying over again the last line, for emphasis:

"The results to date compare favorably to any prior treatment of NDMM:"

Something for any NDMM to consider.